Article Text

Download PDFPDF
Retinal nerve fibre layer and brain grey substance as early prognostic factors for disability in multiple sclerosis
  1. Ana Llorca-Cardeñosa1,4,
  2. María José Magraner-Benedicto2,
  3. Marta J Llorca-Cardeñosa3,
  4. Raquel Bañón1,
  5. Antonio Lleó-Pérez4,
  6. María Dolores Pinazo-Durán4,5
  1. 1Department of Ophthalmology, Castellón General Hospital, Castellón, Spain
  2. 2Department of Neurology, Nueve de Octubre Hospital Valencia, Valencia, Spain
  3. 3Department of Biological Sciences, University of Valencia, Valencia, Spain
  4. 4Ophthalmic Research Unit Santiago Grisolia, Valencia, Spain
  5. 5Department of Surgery-Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain
  1. Correspondence to Dr Ana Llorca, Department of Surgery-Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain; drallorca{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the article by Bock et al,1 in which the association between retinal nerve fibre layer (RNFL) and total macular volume (TMV) was analysed by optical coherence tomography (OCT) and contrast sensitivity was measured by functional acuity contrast testing in relapsing-remitting multiple sclerosis (MS) patients. The authors found that the functional contrast vision in MS is influenced by morphological changes in the anterior visual pathway. This work emphasised that contrast sensitivity is reduced in MS, and that RNFL and TMV, as morphological measures of retinal axon loss, are predictors of contrast sensitivity.

Ophthalmological examinations were the basis of the Bock et al1 study. There …

View Full Text


  • Contributors AL-C and MDP-D jointly conceived, designed and wrote the paper; AL-C, MJM-B and RB performed the experiments, developed analytical tools and conducted neuroimaging analyses; MJL-C and AL-P collected and analysed the data and contributed to interpretation of the results.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was granted by the Clinical Research Ethics Committee of Hospital General de Castellón.

  • Provenance and peer review Not commissioned; internally peer reviewed.